C3 (inflammatory) shows the best prognosis in cancer patients, while C2 (IFN-γ dominant), C1 (wound healing), C4 (lymphocyte depleted), and C6 (TGF-β dominant) exhibit the poor outcome (7). This evidence concerns the gene TGFB1 and cancer.